COVID-19 Support
Gemini Bio Announces Its Dedicated Effort to Help Support COVID-19 Research
* Gemini Bio’s Key Products are Supporting the Fight against COVID-19
WEST SACRAMENTO, CA, April 29, 2020 – Gemini Bioproducts, LLC (“Gemini” or “Gemini Bio”), a leading supplier of cell culture solutions and a portfolio company of BelHealth Investment Partners, LLC (“BelHealth”), a New York-based healthcare private equity firm, today announced its effort to help support COVID-19 research.
According to the WHO, there are over 200 countries with 2.9 million confirmed cases and over 202,000 confirmed deaths, as of the time of this release.
Precision Tools for your COVID-19 Workflow
To support labs pivoting to COVID-19 research, Gemini Bio is prioritizing products and services to assist its customers in four key areas: (1) cell culture, (2) viral harvesting and transport, (3) research tools, and (4) analytical instruments.
| Cell Culture | Viral Harvesting/Transport | Research Tools | Analytical Instruments |
|---|---|---|---|
| Human Serum | Viral Transport Media (Bulk or Custom Fill Sizes) | Cryostorage Medium | Moxi Z Cell Counter |
| Gamma-Irradiated Fetal Bovine Serum | Amphotericin B and Gentamicin | Growth Factors | Moxi GO II Cell Analyzer |
| Custom Media | Hanks’ Balanced Salt Solution (Bulk or Custom Fill Sizes) | Cytokines | |
| Enzymatic Dissociation | Sterile Conical Tubes & Pipettors | Albumins | |
| Bioreactor Solutions |